Identifying the mechanisms of action driving a drug’s anti-cancer efficacy is critical for identifying optimal biomarkers, indications, and combinations for clinical success. Yet, systematically ...
In an analysis of all FDA approvals for anticancer drugs from 2009 to 2020, only about 29% of next-in-class drugs were evaluated in head-to-head randomized clinical trials (RCTs) against their ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results